AI in Pharmaceutical Regulatory Affairs: Use Cases, Benefits, and Limitations
AI in pharmaceutical regulatory affairs is transforming how pharmaceutical companies manage regulatory documentation, submissions, and compliance activities. Artificial intelligence helps regulatory professionals process large volumes of information, identify documentation gaps, and improve operational efficiency. By integrating AI-powered tools into regulatory workflows, organisations can streamline routine activities while supporting accurate and consistent regulatory decision-making.
Key Use Cases of AI in Pharmaceutical Regulatory Affairs
Regulatory Document Review: Analysing regulatory documents to identify missing information, inconsistencies, and potential errors.
Regulatory Intelligence: Monitoring updates from health authorities and identifying changes in regulatory guidelines.
Dossier Management: Supporting the organisation, classification, and review of CTD/eCTD documentation.
Submission Preparation: Assisting with document classification, content extraction, and regulatory information management.
Compliance Monitoring: Helping regulatory teams identify potential compliance gaps and prioritise corrective actions.
Benefits of AI in Regulatory Affairs
Implementing AI in pharmaceutical regulatory affairs can reduce manual workloads, improve document processing speed, and support better information management. AI-powered automation also helps regulatory teams handle repetitive activities, improve consistency, and allocate more time to complex regulatory tasks. These capabilities can improve workflow efficiency and support better regulatory operations.
Limitations and Challenges of AI in Regulatory Affairs
Despite its benefits, AI has certain limitations. AI-generated outputs may contain inaccuracies or misinterpret regulatory requirements. Data privacy, system validation, regulatory acceptance, and integration with existing systems are also important considerations. Human review and expert oversight remain essential for critical regulatory decisions.
How Pharmaceutical Companies Can Adopt AI
Companies should begin by identifying repetitive regulatory activities suitable for automation. They should select appropriate AI solutions, establish data governance practices, and implement validation and review procedures. Regulatory professionals should remain involved in evaluating AI-generated information to ensure accuracy and compliance with applicable requirements.
How MASUU Global Can Support
MASUU Global supports pharmaceutical companies with regulatory affairs services, including regulatory documentation review, authoring, dossier compilation, and submission-related activities. Its support helps organizations manage regulatory documentation, address submission requirements, and strengthen their overall regulatory readiness.
AI in pharmaceutical regulatory affairs offers opportunities to improve documentation management, regulatory intelligence, and submission efficiency. However, successful implementation requires appropriate validation, data protection, and human oversight. Combining AI capabilities with regulatory expertise can help pharmaceutical companies build more efficient and reliable regulatory processes.